Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HMGA2
REST API REST API
Homo sapiens
HMGA2 is differentially expressed in 290 experiments: 121 organism parts: lung, blood, ... (119 more);, 213 disease states: normal, control, ... (211 more);, 94 cell types 535 cell lines 37 compound treatments and 76 other conditions.
Synonyms BABL, LIPO, HMGIC
Orthologs HMGA2 (Gallus gallus)   hmga2 (Danio rerio)   HMGA2 (Bos taurus)   Hmga2 (Mus musculus)   Hmga2 (Rattus norvegicus)   hmga2 (Xenopus laevis)   (Compare orthologs)
InterPro Term AT_hook_DNA-bd_motif, HMGI/HMGY, AT_hook-like
Gene Ontology Term cell division, DNA binding, negative regulation of transcription, DNA-dependent, negative regulation of DNA binding, protein binding, regulation of transcription, DNA-dependent, nucleosomal DNA binding, stem cell differentiation, positive regulation of cell proliferation, positive regulation of gene expression, negative regulation of apoptosis, DNA-(apurinic or apyrimidinic site) lyase activity, nuclear chromosome, spermatogenesis, male gonad development, DNA bending activity, positive regulation of multicellular organism growth, positive regulation of apoptosis, transcription factor binding, cell cycle, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, nucleus, somatic stem cell maintenance, mitosis, SMAD binding, chromatin, base-excision repair, negative regulation of transcription from RNA polymerase II promoter, chromosome condensation, chromatin organization, epithelial to mesenchymal transition, positive regulation of transcription, DNA-dependent, heterochromatin formation, regulation of growth, AT DNA binding, DNA damage response, detection of DNA damage, mesenchymal cell differentiation, pituitary gland development, cell proliferation in forebrain, adipose tissue development, chondrocyte differentiation, adrenal gland development, fat cell differentiation, C2H2 zinc finger domain binding, mitotic cell cycle G2/M transition DNA damage checkpoint, negative regulation by host of viral transcription, protein-DNA complex, response to virus, mesodermal cell differentiation, 5'-deoxyribose-5-phosphate lyase activity, negative regulation of astrocyte differentiation, regulation of growth hormone secretion, positive regulation of cell cycle arrest, DNA-dependent protein kinase activity, cAMP response element binding, mesodermal-endodermal cell signaling, regulation of stem cell maintenance, regulation of cell cycle process, negative regulation of retroviral genome replication, fat pad development, protein binding transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription, core promoter binding, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, positive regulation of transcription regulatory region DNA binding, nucleic acid binding transcription factor activity, positive regulation of stem cell proliferation, regulatory region DNA binding, SMAD protein complex, positive regulation of cellular senescence, MH1 domain binding, chromosome breakage, regulation of peptide hormone secretion, senescence-associated heterochromatin focus formation, regulation of cellular response to drug, endodermal cell differentiation, MH2 domain binding, positive regulation of response to DNA damage stimulus, histone H2A-S139 phosphorylation, positive regulation of cellular response to X-ray, negative regulation of double-strand break repair via nonhomologous end joining, chondrocyte proliferation, senescence-associated heterochromatin focus, oncogene-induced senescence
Gene-Disease Assocation LIPOMATOSIS, MULTIPLE, STATURE QUANTITATIVE TRAIT LOCUS 9; STQTL9, LEIOMYOMA, UTERINE; UL
UniProt Accession B2KX87, Q8IZX8, Q1M185, Q1M182, Q1M188, Q1M187, Q1M186, P52926, F5H2A4, F5H6H0, F5H2U8
Search EB-eye ENSG00000149948
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (48 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
HL-60
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258
SW480
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37
NCI-H929
2
E-MEXP-1269, E-MTAB-62
A549
2
E-GEOD-6013, E-GEOD-3202
AGS
2
E-MTAB-37, E-GEOD-15460
529 more value(s).


Cell type

studied in E-MEXP-2426, E-GEOD-21668, E-GEOD-19397, E-MEXP-120, E-GEOD-4219, ... (45 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-GEOD-6740, E-MTAB-25
neuroepithelial cell
1
E-MEXP-2426
monolayer recovery
1
E-GEOD-4219
B cell precursor
1
E-MEXP-120
CD8+ cell
1
E-GEOD-7307
erythropoietic
1
E-GEOD-9894
88 more value(s).


Disease state

studied in E-GEOD-15960, E-GEOD-2466, E-GEOD-3678, E-GEOD-20168, E-MTAB-62, ... (55 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
embryonal rhabdomyosarcoma
2
E-MTAB-62, E-MEXP-121
glioblastoma
2
E-GEOD-6014, E-GEOD-4290
papillary thyroid carcinoma
2
E-GEOD-3467, E-GEOD-3678
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
207 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-GEOD-3356, E-GEOD-5824, ... (24 experiments)

Factor Value U/D Experiments
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
ethanol
2
E-MEXP-2241, E-GEOD-3113
none
3
4
E-GEOD-5741, E-GEOD-412, E-GEOD-5824, E-MEXP-2285, E-GEOD-3306, ... (7 experiments)
cadmium chloride 2.5-hydrate
1
E-GEOD-6907
glutamine
1
E-MEXP-1335
nebivolol
1
E-GEOD-3356
31 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
38
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-6236, E-GEOD-2666, ... (7 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-2509, E-TABM-147, E-GEOD-21138, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-MEXP-1437, E-GEOD-2466, E-GEOD-22593, E-TABM-868, E-TABM-601, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-21612, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-GEOD-837, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-TABM-15, E-GEOD-16363, ... (26 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

No of metastases
studied in E-GEOD-22541

No of pulmonary metastases
studied in E-GEOD-22541

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19246, E-GEOD-1343

Qrt pcr areg dct
studied in E-GEOD-5851

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-8167

Processing time: 0.272 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM